<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527202</url>
  </required_header>
  <id_info>
    <org_study_id>BTXneurop-1</org_study_id>
    <nct_id>NCT00527202</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Botox to Treat Neuropathic Pain</brief_title>
  <official_title>Randomized Placebo-Controlled Study of the Efficacy of Botulinum Toxin Type A (Botox) in Spontaneous Pain and Allodynia Related to Traumatic Nerve Injury or Postherpetic Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Ambroise Paré Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Ambroise Paré Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives : to investigate the analgesic effects and safety of intradermal botulinum toxin A
      injection in the treatment of focal painful neuropathies (eg, postherpetic neuralgia, nerve
      trauma)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be randomized, performed in parallel group and double blind versus saline and
      will include 30 patients. Botulinum toxin injection will be injected intradermally in the
      painful area (one single injection) following a method adapted from that used in
      hyperhidrosis. The patients will be followed for 6 months after the injection. Primary
      outcome will be self-reported pain from the patients diaries. Secondary outcomes will be
      neuropathic symptoms, quality of life, allodynia to brush and pressure, detection and pain
      thresholds, proportion of responders, pain relief and clinical global impression. Clinical
      assessment will take place before injection then at 1 month, 3 months and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported pain (numerical scales) on patients diaries</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean pain (VAS) at each visit Quality of life Proportion of responders % pain relief Clinical global impression Assessment of blindedness</measure>
    <time_frame>prospective</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <condition>Nerve Trauma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin A and saline</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  daily pain for at least 6 months of at least moderate intensity clearly attributed to
             the nerve lesion

          -  limited area of pain

          -  mechanical allodynia in the painful area

        Exclusion Criteria:

          -  contraindication to BTXA formulation

          -  coagulation disorders

          -  another painful condition

          -  current major depression

          -  history of drug or alcohol abuse

          -  compensation claim or litigation

          -  facial neuropathic pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier BOUHASSIRA, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>INSERM U 792</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danièle RANOUX, MD</last_name>
    <role>Study Chair</role>
    <affiliation>hôpital de Limoges (FRANCE)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré, AP-HP</name>
      <address>
        <city>Boulogne-billancourt</city>
        <zip>92100f</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>September 7, 2007</last_update_submitted>
  <last_update_submitted_qc>September 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

